Retinoblastoma - Pipeline Review, H2 2017

  • ID: 4419028
  • Report
  • 55 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Icon Bioscience Inc
  • Ophthotech Corp
  • PepVax Inc
  • Recombio SL
  • VCN Biosciences SL
  • MORE
Retinoblastoma - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Retinoblastoma - Pipeline Review, H2 2017, provides an overview of the Retinoblastoma (Oncology) pipeline landscape.

Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Retinoblastoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Retinoblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinoblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Retinoblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Retinoblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinoblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Retinoblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinoblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinoblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinoblastoma (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinoblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinoblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Icon Bioscience Inc
  • Ophthotech Corp
  • PepVax Inc
  • Recombio SL
  • VCN Biosciences SL
  • MORE
Introduction

Retinoblastoma - Overview

Retinoblastoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Retinoblastoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinoblastoma - Companies Involved in Therapeutics Development

Icon Bioscience Inc

Innovation Pharmaceuticals Inc

Ophthotech Corp

PepVax Inc

Recombio SL

VCN Biosciences SL

Retinoblastoma - Drug Profiles

FL-761 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kevetrin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melphalan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nutlin-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegpleranib sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PVX-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

racotumomab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCN-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Retinoblastoma - Dormant Projects

Retinoblastoma - Product Development Milestones

Featured News & Press Releases

Jul 26, 2017: Ophthotech Announces Update on Fovista

Feb 29, 2016: VCN Biosciences Provides Update on its lead candidate VCN-01

Dec 01, 2015: Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma

Nov 23, 2015: Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma

Aug 23, 2015: Cellceutix Requesting Meeting With FDA on Kevetrin for Pediatric Retinoblastoma

Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma

Jan 03, 2013: Icon's Melphalan Intraocular Injection Receives US Orphan Drug Designation For Treatment Of Retinoblastoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Retinoblastoma, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Retinoblastoma - Pipeline by Icon Bioscience Inc, H2

Retinoblastoma - Pipeline by Innovation Pharmaceuticals Inc, H2

Retinoblastoma - Pipeline by Ophthotech Corp, H2

Retinoblastoma - Pipeline by PepVax Inc, H2

Retinoblastoma - Pipeline by Recombio SL, H2

Retinoblastoma - Pipeline by VCN Biosciences SL, H2

Retinoblastoma - Dormant Projects, H2

List of Figures

Number of Products under Development for Retinoblastoma, H2

Number of Products under Development by Companies, H2

Number of Products by Targets, H2

Number of Products by Stage and Targets, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Icon Bioscience Inc
  • Innovation Pharmaceuticals Inc
  • Ophthotech Corp
  • PepVax Inc
  • Recombio SL
  • VCN Biosciences SL
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll